About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
CRSP - CRISPR Therapeutics ...| Previous Close | $199.88 | Open | $207.09 |
| Volume | 232.9K | Market Cap | 14.233B |
| Yield | Last Dividend |
| CRISPR Therapeutics Has Soared in Just a... | 01/14/21 |
| This is a time to nail down profits???.CRSP | |
| Covid-19 Impact On CRISPR and CAS Gene M... | 01/11/21 |
| COHERENT MARKET INSIGHTS has added a new report titled Global CRISPR and CAS Gene Market with analysis provides the insights which bring marketplace c... | |
| Study Describes New Way to Place CRISPR/... | 01/07/21 |
| Clusters of regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 nuclease (Cas9) is an innovative genome editing tool ... | |
| The Best Stock Picker of 2020 Wins With ... | 12/31/20 |
| (Bloomberg Opinion) -- Everyone should know Cathie Wood by now.That's because whatever benefits central bankers bequeathed to shareholders with next-t... | |
| Real Retirement Secrets: Your Most Impor... | 12/30/20 |
| I feature a lot of big winners over the years inside IBI. Some of our big winners include TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP), CryoPort... | |
| The Daily Biotech Pulse: FDA Nod For Amp... | 12/29/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Acl... | |
| IBI Blogs On Retirement Secrets: Three C... | 12/27/20 |
| Some of our big winners include TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP), CryoPort (CYRX), Intra-Cellular Therapies (ITCI), Axsome Therapeut... | |
| The ENTR ETF: Once Incurable Afflictions... | 12/17/20 |
| The healthcare sector has been solid in 2020, but the truly impressive gains are coming by way of the companies disrupting the industry. Investors loo... | |
| Bradley J. Phd Bolzon Sells 33,000 Share... | 12/16/20 |
| CRISPR Therapeutics AG (NASDAQ:CRSP) Director Bradley J. Phd Bolzon sold 33,000 shares of the stock in a transaction on Thursday, December 10th. The s... | |
| Impact Analysis Coronavirus On CRISPR an... | 12/16/20 |
| Manufacturers in the CRISPR and CAS gene are collaborating with many companies for sponsoring clinical trials. Editas Medicine has licensed CRISPR and... | |
| Garvin Jabusch and Jeremy Deems doubled ... | 12/15/20 |
| Summary List Placement Jeremy Deems and Garvin Jabusch frame their entire investing philosophy around one straightforward axiom: solutions to problems... | |
| CRISPR Therapeutics Receives Grant to Ad... | 12/14/20 |
| -Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients??? | |
| CRISPR Technology Market Growing Demand ... | 12/08/20 |
| The global CRISPR technology market reached a value of nearly $685.5 million in 2019, having increased at a compound annual growth rate (CAGR) of 35.0... | |
| Top Analyst Upgrades and Downgrades: Acc... | 12/07/20 |
| Monday's top analyst upgrades and downgrades included Accenture, Boeing, CRISPR Therapeutics, DraftKings, Illumina, Lyft, McDonald's, Southwest Airlin... | |
| Canaccord Genuity Stick to Their Buy Rat... | 12/07/20 |
| Canaccord Genuity Stick to Their Buy Rating for Crispr Therapeutics AG | |
| #ASH20: David Altshuler and the Vertex/C... | 12/05/20 |
| Back in the mid-80s, David Altshuler worked in Richard Mulligan???s famous Harvard lab, focused on hemoglobinopathies and the glimmering promise of a ... | |
| The Daily Biotech Pulse: Pfizer-BioNTech... | 12/02/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 1) AbbV... | |
| Global Gene Therapy for Blood Disorders ... | 11/20/20 |
| InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on ???Global Gene Therapy for Blood Disorders Market Assessment ??... | |
| CRISPR and CAS Gene Market Revenue Devel... | 11/03/20 |
| CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) genes are essential for the adaptive immunity in few ba... | |
| Crispr Therapeutics Earnings Report: Her... | 10/26/20 |
| Crispr Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Crispr Therapeutics (NASDAQ:CRSP) Price ... | 10/24/20 |
| Crispr Therapeutics (NASDAQ:CRSP) had its price target lifted by Roth Capital from $105.00 to $115.00 in a research report sent to investors on Wednes... | |
| Crispr Therapeutics (NASDAQ:CRSP) Price ... | 10/24/20 |
| Crispr Therapeutics (NASDAQ:CRSP) had its price target upped by Piper Sandler from $104.00 to $128.00 in a report released on Wednesday morning, The F... | |
| Crispr Therapeutics AG (NASDAQ:CRSP) Giv... | 10/24/20 |
| Shares of Crispr Therapeutics AG (NASDAQ:CRSP) have received an average rating of ???Buy??? from the twenty-one ratings firms that are presently cover... | |
| Contrasting Neurocrine Biosciences (NASD... | 10/24/20 |
| Neurocrine Biosciences (NASDAQ:NBIX) and Crispr Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better business? We wi... | |
| Stifel Nicolaus Boosts Crispr Therapeuti... | 10/24/20 |
| Crispr Therapeutics (NASDAQ:CRSP) had its price target hoisted by Stifel Nicolaus from $75.00 to $93.00 in a report released on Wednesday, The Fly rep... | |
| Roth Capital Boosts Crispr Therapeutics ... | 10/24/20 |
| Crispr Therapeutics (NASDAQ:CRSP) had its price objective boosted by Roth Capital from $105.00 to $115.00 in a report published on Wednesday morning, ... | |
| Crispr Therapeutics (NASDAQ:CRSP) Price ... | 10/23/20 |
| Crispr Therapeutics (NASDAQ:CRSP) had its price objective lifted by analysts at Canaccord Genuity from $110.00 to $120.00 in a research report issued ... | |
| Piper Sandler Raises Crispr Therapeutics... | 10/23/20 |
| Crispr Therapeutics (NASDAQ:CRSP) had its target price boosted by Piper Sandler from $104.00 to $128.00 in a research note published on Wednesday morn... | |
| Crispr Therapeutics (NASDAQ:CRSP) PT Rai... | 10/23/20 |
| Crispr Therapeutics (NASDAQ:CRSP) had its target price upped by research analysts at Canaccord Genuity from $110.00 to $120.00 in a report issued on T... | |
| Crispr Therapeutics (NASDAQ:CRSP) PT Rai... | 10/23/20 |
| Crispr Therapeutics (NASDAQ:CRSP) had its target price boosted by Chardan Capital from $100.00 to $110.00 in a research report issued to clients and i... | |
| Buy rating | 12/10/20 |
| Needham maintains Buy rating and raises Price Target from $105.00 to $170.00 | |
| Buy rating | 12/10/20 |
| Chardan Capital maintains Buy rating and raises Price Target from $110.00 to $166.00 | |
| Hold rating | 12/07/20 |
| Wells Fargo downgrades from Overweight to Equal-Weight rating and announces Price Target of $145.00 | |
| Buy rating | 12/07/20 |
| Roth Capital maintains Buy rating and raises Price Target from $115.00 to $170.00 | |
| Strong Buy rating | 10/29/20 |
| Piper Sandler maintains Overweight rating and lowers Price Target from $128.00 to $107.00 | |
| Hold rating | 10/23/20 |
| RBC Capital initiates coverage with Sector Perform rating and announces Price Target of $110.00 | |
| Buy rating | 10/22/20 |
| Chardan Capital maintains Buy rating and raises Price Target from $100.00 to $110.00 | |
| Date | 2020-10-28 (AMC) | Est. (EPS/Rev.) | ($1.18)/ 2.06M |
| Actual (EPS/Rev.) | $-1.32/ $148.00 K | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Trading | Trading | 99.00 % | Follow |
| FEAT. PIMP C | JOHN KROLIKOWSKI JR | 88.00 % | Follow |
| WIDE AWAKE | JOHN KROLIKOWSKI JR | 80.00 % | Follow |
| Swing for the fences | Gino Baldassano | 72.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
